

## SENATE SUMMARY OF HOUSE AMENDMENTS

SB 118

2022 Regular Session

Talbot

## KEYWORD AND SUMMARY AS RETURNED TO THE SENATE

HEALTH/ACC INSURANCE. Requires medical necessity for genetic testing of certain cancer mutations is based on nationally recognized clinical practice guidelines. (1/1/23)

## SUMMARY OF HOUSE AMENDMENTS TO THE SENATE BILL

1. Adds that biomarker tests may be supported for coverage by nationally recognized consensus statements and clinical practice guidelines provided by the National Comprehensive Cancer Network or the American Society of Clinical Oncology.
2. Modifies the definition of "biomarker testing" to include whole exome and whole transcriptome sequencing.
3. Makes technical changes including modifications to the definitions of "consensus statements" and "nationally recognized clinical practice guidelines".
4. Excludes plans offered through the office of group benefits from definition of a "health coverage plan".

## DIGEST OF THE SENATE BILL AS RETURNED TO THE SENATE

## DIGEST

SB 118 Engrossed

2022 Regular Session

Talbot

Present law requires a health coverage plan in this state to include coverage for genetic or molecular testing for cancer including but not limited to tumor mutation testing, next generation sequencing, hereditary germline mutation testing, pharmacogenomic testing, whole exome and genome sequencing, and biomarker testing. Proposed law retains present law.

Present law provides that coverage may be subject to annual deductibles, coinsurance, and copayments established under a health coverage plan. Proposed law retains present law.

Present law provides that coverage may be subject to applicable evidence-based medical necessity criteria of a health coverage plan. Proposed law deletes present law.

Proposed law requires coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an individual's disease or condition when the diagnostic test is supported in certain respects by any of the following: the U.S. Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services National Coverage Determinations, Medicare Administrative Contractor Local Coverage Determinations, National Comprehensive Cancer Network, or American Society of Clinical Oncology.

Present law defines "biomarker testing". Proposed law expands the definition to include whole exome and whole transcriptome sequencing. Otherwise retains the present law definition.

Present law defines "health coverage plan" but proposed law provides that "health coverage plan" does not include any plan offered through the office of group benefits.

Proposed law defines "consensus statements" and "nationally recognized clinical practice guidelines".

Effective on January 1, 2023.

(Amends R.S. 22:1028.3(B)(2), (C), and (D)(intro. para.) and (2); Adds R.S. 22:1028.3(D)(3) and (4))

---

Thomas L. Tyler  
Senate Counsel